Novel applications of nanotechnology in medicine

Indian Journal of Medical Research

Volumn 130, Issue 6, 2009, Pages 689-701

  Surendiran, A ^a   Sandhiya, S ^a   Pradhan, S C ^a   Adithan, C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Diagnostics; Drugs; Nanomedicine; Nanotechnology; Therapeutics

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBON NANOTUBE; CHITOSAN; CISPLATIN; DENDRIMER; DOXORUBICIN; FOLIC ACID; FULLERENE DERIVATIVE; HAMYCIN; IMMUNOLIPOSOME; INSULIN; LIPOSOME; METHOTREXATE; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOBUBBLE; NANOPARTICLE; NANOSHELL; NANOTUBE; PACLITAXEL; PRODRUG; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; VACCINE;

BREAST CANCER; CLINICAL PROTOCOL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSPORT; ERYTHROCYTE; GENE THERAPY; HEALTH HAZARD; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEISHMANIASIS; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROBIVORE; MYCOSIS; NANOMEDICINE; NANOPORE; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; OVARY TUMOR; RESPIROCYTE; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS INFECTION;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIPOSOMES; NANOMEDICINE; NANOSTRUCTURES;

EID: 74349092992     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150: 552-8.
2. Gregoriadis G, Ryman BE. Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases. Eur J Biochem 1972; 24: 485-91.
3. McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in- liposomes - a novel concept in drug-delivery. Int J Pharm 1994; 112: 249-58.
4. Illum L, Davis SS. The organ uptake of intravenously administered colloidal particles can be altered using a non- ionic surfactant (Poloxamer 338). FEBS Lett 1984; 167: 79-82.
5. Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma-protein and clearance from the circulation - studies with poly (ethylene glycol)-coated vesicles. Biochim Biophys Acta 1991; 1062: 77-82.
6. Kirby C, Gregoriadis G. The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection in mice. Biochem Pharmacol 1983; 32: 609-15.
7. Torchilin VP, Shtilman MI, Trubetskoy VS, Whiteman K, Milstein AM. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta 1994; 1195: 181-4.
8. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992; 52: 3255-61.
9. Torchilin VP, Trubetskoy VS, Milshteyn AM, Canillo J, Wolf GL, Papisov MI. Targeted delivery of diagnostic agents by surface modified liposomes. J Control Rel 1994; 28: 45-58.
10. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT. Antibody directed enzyme prodrug therapy (ADEPT) - clinical report. Dis Markers 1991; 9: 233-8.
11. Vingerhoeds MH, Haisma HJ, van MM, van de Rijt RB, Crommelin DJ, Storm G. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno- enzymosomes) for site-specific activation of prodrugs. FEBS Lett 1993; 336: 485-90.
12. Vingerhoeds MH, Haisma HJ, Belliot SO, Smit RH, Crommelin DJ, Storm G. Immunoliposomes as enzyme-carriers (immuno- enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm Res 1996; 13: 604-10.
13. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001; 7: 3314-24.
14. Forssen E, Willis M. Ligand-targeted liposomes. Adv Drug Del Rev 1998; 29: 249-71.
15. Kole L, Sarkar K, Mahato SB, Das PK. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochem Biophys Res Commun 1994; 200: 351-8.
16. Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998; 27: 772-8.
17. Desai TA, Chu WH, Tu JK, Beattie GM, Hayek A, Ferrari M. Microfabricated immunoisolating biocapsules. Biotechnol Bioeng 1998; 57: 118-20.
18. Leoni L, Desai TA. Nanoporous biocapsules for the encapsulation of insulinoma cells: biotransport and biocompatibility considerations. IEEE Trans Biomed Eng 2001; 48: 1335-41.
19. Freitas RA. Current status of nanomedicine and medical nanorobotics. J Comput Theor Nanosci 2005; 2: 1-25.
20. Deamer DW, Akeson M. Nanopores and nucleic acids: prospects for ultrarapid sequencing. Trends Biotechnol 2000; 18: 147-51.
21. Thakral S, Mehta RM. Fullerenes: an introduction and overview of their biological properties. Indian J Pharm Sci 2006; 68: 13-9.
22. Kratschmer W, Lamb LD, Fostiropoulos K, Hoffman DR. Solid C60: a new form of carbon. Nature 1990; 347: 354-8.
23. Taylor R, Hare JP, Abdul-Sada AK, Kroto HW. Isolation, separation and characterisation of the fullerenes C60 and C70: the third form of carbon. J Chem Soc Chem Commun 1990; 20: 1423-5.
24. Chandrakumar KR, Ghosh SK. Alkali-metal-induced enhancement of hydrogen adsorption in C60 fullerene: an ab Initio study. Nano Lett 2008; 8: 13-9.
25. Fatouros PP, Corwin FD, Chen ZJ, Broaddus WC, Tatum JL, Kettenmann B, et al. Invitro and invivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology 2006; 240: 756-64.
26. Komatsu K, Murata M, Murata y. Encapsulation of molecular hydrogen in fullerene C60 by organic synthesis. Science 2005; 307: 238-40.
27. Mroz P, Pawlak A, Satti M, Lee H, Wharton T, Gali H, et al. Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radic Biol Med 2007; 43: 711-9.
28. Tegos GP, Demidova TN, Arcila-Lopez D, Lee H, Wharton T, Gali H, et al. Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol 2005; 12: 1127-35.
29. Bosi S, Da RT, Castellano S, Banfi E, Prato M. Antimycobacterial activity of ionic fullerene derivatives. Bioorg Med Chem Lett 2000; 10: 1043-5.
30. Ji H, yang Z, Jiang W, Geng C, Gong M, Xiao H, et al. Antiviral activity of nano carbon fullerene lipidosome against influenza virus in vitro. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 243-6.
31. Cai X, Jia H, Liu Z, Hou B, Luo C, Feng Z et al. Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+)-induced cellular model of Parkinson's disease. J Neurosci Res 2008; 86: 3622-34.
32. Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 2008; 29: 3561-73.
33. Chen BX, Wilson SR, Das M, Coughlin DJ, Erlanger BF. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc Natl Acad Sci USA 1998; 95: 10809-13.
34. Iijima S. Helical microtubules of graphitic carbon. Nature 1991; 354: 56-8.
35. Reilly RM. Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine. J Nucl Med 2007; 48: 1039-42.
36. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007; 48: 1180-9.
37. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008; 41: 60-8.
38. Zhang Z, yang X, Zhang Y, Zeng B, Wang S, Zhu T, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006; 12: 4933-9.
39. Pantarotto D, Partidos CD, Graff R, Hoebeke J, Briand JP, Prato, M et al. Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. J Am Chem Soc 2003; 125: 6160-4.
40. Balasubramanian K, Burghard M. Biosensors based on carbon nanotubes. Anal Bioanal Chem 2006; 385: 452-68.
41. Reilly RM. Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine. J Nucl Med 2007; 48: 1039-42.
42. Iga AM, Robertson JH, Winslet MC, Seifalian AM. Clinical potential of quantum dots. J Biomed Biotechnol 2007; 2007: 76087-97.
43. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In-vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnol 2004; 22: 969-76.
44. Amiot CL, Xu S, Liang S, Pan L, Zhao JX. Near-infrared fluorescent materials for sensing of biological targets. Sensors 2008; 8: 3082-105.
45. West JL, Halas NJ. Applications of nanotechnology to biotechnology commentary. Curr Opin Biotechnol 2000; 11: 215-7.
46. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003; 100: 13549-54.
47. Lowery AR, Gobin AM, Day ES, Halas NJ, West JL. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomedicine 2006; 1: 149-54.
48. Kherlopian AR, Song T, Duan Q, Neimark MA, Po MJ, Gohagan JK, et al. A review of imaging techniques for systems biology. BMC Syst Biol 2008; 2: 74-92.
49. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol 2006; 41: 354-62.
50. Gao Z, Kennedy AM, Christensen DA, Rapoport Ny. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics 2008; 48: 260-70.
51. Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 2007; 99: 1095-106.
52. Negishi Y, Endo Y, Fukuyama T, Suzuki R, Takizawa T, Omata D, et al. Delivery of siRNA into the cytoplasm by liposomal bubbles and ultrasound. J Control Release 2008; 132: 124-30.
53. Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Maruyama K. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm 2008; 354: 49-55.
54. Iverson N, Plourde N, Chnari E, Nackman GB, Moghe PV. Convergence of nanotechnology and cardiovascular medicine: progress and emerging prospects. BioDrugs 2008; 22: 1-10.
55. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006; 107: 459-66.
56. Peng XH, Qian X, Mao H, Wang AY, Chen Z, Nie S, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008; 3: 311-21.
57. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49: 403-8.
58. Leuschner C, Kumar C, Urbina MO. The use of ligand conjugated supraparamagnetic iron oxide nanoparticles for early detection of metastasis. NSTI Nanotechnol 2005; 1: 5-6.
59. Knauth M, Egelhof T, Roth SU, Wirtz CR, Sartor K. Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. AJNR Am J Neuroradiol 2001; 22: 99-102.
60. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997; 7: 1140-5.
61. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989; 152: 167-73.
62. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 2003; 301: 1884-6.
63. Aduro Biotech. Berkeley: Oncologic and Triton BioSystems Merge to Form Aduro BioTech Aduro to Focus on NT™ and TNT™ Systems for Solid Tumor Cancers. 2008. Available from: http://www.tritonsys. com/news/Aduro.pdf, accessed on May 16, 2009.
64. Xu H, yan F, Monson EE, Kopelman R. Room-temperature preparation and characterization of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications. J Biomed Mater Res A 2003; 66: 870-9.
65. NCI Alliance for Nanotechnology in Cancer Rockville: Nanotechnology Tackles Brain Cancer. 2005, Available from http://nanocancergov/news_center/monthly_feature_2005_decasp#top, accessed on September 14, 2008.
66. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19: 311-30.
67. Baker JR, Quintana A, Piehler L, Banazak-Holl, Tomalia D, Raczka E. The synthesis and testing of anti-cancer therapeutic nanodevices. Biomed Microdevices 2001; 3: 61-9.
68. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007; 21: 1117-25.
69. Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007; 67: 8156-63.
70. Starpharma Holding Ltd, Melbourne: First commercial product launch of Starpharma's DNT Priostar dendrimers. 2008 [updated 2008 April 22] Available from: http://www.ausbiotech.org/data/downloads/ Starpharma%20-20first%20commercial%20launch%20of%20DNT%20Priostar% 20den drimers,%2022%20April%202008.pdf, accessed on May 16, 2009.
71. Quiagen California: SuperFect Transfection Reagent. Available from:http://www1.qiagen.comProducts/Transfection/TransfectionReagents/SuperFectTransfectionReagent.aspx# Tabs=t1, accessed on May 3, 2008.
72. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007; 35: 61-7.
73. Calabretta MK, Kumar A, McDermott AM, Cai C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules 2007; 8: 1807-11.
74. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomed 2008; 3: 703-17.
75. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005; 57: 2215-37.
76. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005; 57: 2106-29.
77. Niu L, Xu YC, Dai Z, Tang HQ. Gene therapy for type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene. World J Gastroenterol 2008; 14: 4209-15.
78. Davis PB, Cooper MJ. Vectors for airway gene delivery. AAPS J 2007; 9: E11-7.
79. Pathak A, Vyas SP, Gupta KC. Nano-vectors for efficient liver specific gene transfer. Int J Nanomedicine 2008; 3: 31-49.
80. Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004; 103: 85-92.
81. Freitas Jr RA. Exploratory design in medical nanotechnology: a mechanical artifcial red cell. Artif Cells Blood Substit Immobil Biotechnol 1998; 26: 411-30.
82. Freitas Jr RA. A Mechanical Artificial Red Cell: Exploratory Design in Medical Nanotechnology [serial on the internet] Available from: http://www.foresight.org/nanomedicine/Respirocytes4.html#Sec610, accessed on September 29, 2008.
83. Freitas Jr RA. Microbivores: artifcial mechanical phagocytes using digest and discharge protocol. J Evol Technol 2005; 14: 1-52.
84. Nijhara R, Balakrishnan K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine 2006; 2: 127-36.
85. US. Food and Drug Administration Rockville: Center for Devices and Radiological Health. 21 Code of Federal Regulations; Parts 210 and 211. 996 [updated 2005 Dec 6] Available from: http://www.fda. gov/cder/dmpq/cgmpregs. htm, accessed on May 11, 2009.
86. US. Food and Drug Administration Rockville: Center for Devices and Radiological Health. Code of Federal Regulations. 21CFR211.25. 2008 [updated 2008 April 1]. Available from: http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=211.25, accessed on May 11, 2009.
87. US. Food and Drug Administration Rockville: Center for Devices and Radiological Health. Code of Federal Regulations. 21CFR211.72. 2008 [updated 2008 April 1]. Available from: http://www.accessdata.fda. gov/scripts/ cdrh/cfdocs/cfcfrCFRS earch.cfm?fr=211.72, accessed on May 11, 2009.
88. Miller J. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Sci Technol Law Rev 2003; 4: E5-40.
89. Li Z, Hulderman T, Salmen R, Chapman R, Leonard SS, Young SH, et al Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ Health Perspect 2007; 115: 377-82.
90. Lam CW, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 2004; 77: 126-34.
91. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 2004; 112: 1058-62.
92. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006; 114: 1172-8.
93. Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004; 16: 437-45.
94. Radomski A, Jurasz P, onso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005; 146: 882-93.
95. Chen Z, Meng H, Xing G, Chen C, Zhao Y, Jia G, et al. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett 2006; 163: 109-20.